Adenoid Cystic Carcinoma clinical trials at UC Cancer
2 research studies open to eligible people
A Study of the Drug ONC-392 in Advanced Solid Tumors and Lung Cancer
open to eligible people ages 18 years and up
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.
at UC Davis
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: The SOLAR Trial
open to eligible people ages 18 years and up
The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: - Stereotactic Body Radiation Therapy (SBRT)
at UCSF
Our lead scientists for Adenoid Cystic Carcinoma research studies include Tianhong Li, MD Sue Yom, MD, PhD.